RecoveryResearch Phase

FGL Peptide

Subcutaneous injection, Intranasal

Overview

FGL peptide is a 15-amino acid synthetic sequence derived from the neural cell adhesion molecule (NCAM) that mimics the fibronectin-like domain. It promotes neurite outgrowth and synaptic plasticity by engaging NCAM and fibroblast growth factor receptors without requiring direct cell-cell adhesion.

Mechanism of Action

The peptide has been investigated for neuroprotective and cognitive-enhancing properties in models of neurological injury and disease..

Research Summary & Key Findings

Preclinical rodent studies have demonstrated improved spatial learning and memory in models of aging and neurodegeneration. Research published in the Journal of Neuroscience and related journals has shown FGL enhances hippocampal long-term potentiation and protects against excitotoxic injury. Human clinical trials have not been reported in peer-reviewed literature.

Clinical Status

Research Phase

FGL Peptide is in the research phase with limited clinical data in humans. Current evidence is primarily derived from preclinical (animal or in vitro) studies.

Administration Routes

Subcutaneous injectionIntranasal

Related Peptides in Recovery

Find a Provider

Find a verified provider who offers FGL Peptide therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply FGL Peptide.

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.